
EHA 2020: Advances in treatment of high-risk chronic lymphocytic leukaemia
Prognosis in high risk Chronic Lymphocytic Leukemia (CLL) is still unsatisfactory. Despite the availability of…
Prognosis in high risk Chronic Lymphocytic Leukemia (CLL) is still unsatisfactory. Despite the availability of…
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown…
Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common…
People who inherit genetic variants affecting the function of their immune system are at increased…
A new anti-cancer drug with the power to ‘melt away’ certain advanced forms of chronic…
Eight of 14 patients in the first trial of the University of Pennsylvania’s personalised cellular…